《大行》摩通:康方生物(09926.HK)肺癌试验最终分析有望达标 评级“增持”

阿斯达克财经
May 06

摩根大通发表研究报告,康方生物(09926.HK) 合作伙伴Summit(SMMT.US)  日前公布HARMONi-3鳞状队列中期无进展生存期分析未达统计显著性,相关消息拖累Summit上周五(1日)股价下跌约25%。该行认为该肺癌试验中期分析未达标并非重大负面意外,因试验设计的统计阈值较高,最终无进展生存期分析预计于2026年下半年进行,成功率较高。摩通维持康方生物“增持”评级,目标价162...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10